Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mario Leyba

Surgery Albuquerque, NM Medical Doctor

NPI 1689876013 CMS profile 1123094

6701 Jefferson St Ne, Albuquerque, NM 87109

Open in the dashboard

General payments

$1,244,946

1,702 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$22,131 paid to institutions, not to them · program year 2023

Through program year 2025, Mario Leyba of Albuquerque, NM is reported in the CMS Open Payments database as having received $1,244,946 across 1,702 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $22,131 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $273,215 329
2024 General $205,236 321
2023 General $212,616 286
2022 General $274,046 350
2021 General $106,856 140
2020 General $39,993 66
2019 General $132,983 210

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mario Leyba
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Mario Leyba were reported at $273,215. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Mario Leyba Surgery median Middle half National median
2019 $132,983 $253 $82–$1,521 $163
2020 $39,993 $131 $40–$706 $114
2021 $106,856 $168 $50–$904 $132
2022 $274,046 $224 $76–$1,218 $149
2023 $212,616 $253 $82–$1,255 $160
2024 $205,236 $279 $90–$1,381 $164
2025 $273,215 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $1,141,178 1,416 payments
  2. W. L. Gore & Associates, Inc. $72,496 164 payments
  3. CONMED Corporation $14,704 11 payments
  4. Smith+Nephew, Inc. $6,988 23 payments
  5. TELA Bio, Inc. $3,113 30 payments
  6. Pacira Pharmaceuticals Incorporated $2,720 6 payments
  7. Davol Inc. $2,372 18 payments
  8. Ethicon US, LLC $542 15 payments
  9. Merck Sharp & Dohme Corporation $223 6 payments
  10. Becton, Dickinson and Company $129 1 payment
  11. Other $480 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $853,192 312 payments
  2. Travel and Lodging $159,978 710 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $119,245 57 payments
  4. Food and Beverage $56,166 585 payments
  5. Consulting Fee $56,123 33 payments
  6. Gift $242 5 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $1,123,078 1,404 payments
  2. GORE SYNECOR Biomaterial $59,445 78 payments
  3. GORE ENFORM Preperitoneal Biomaterial $44,464 35 payments
  4. GORE BIO-A Tissue Reinforcement $36,900 50 payments
  5. DA VINCI SP $18,100 12 payments
  6. AirSeal $10,785 1 payment
  7. GORE DUALMESH Biomaterial $7,863 3 payments
  8. STRAVIX PL $5,896 5 payments
  9. STRAVIX $5,590 2 payments
  10. STRAVIX MESH $5,500 1 payment
  11. Other $21,378 158 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$101,643

Medicare's payments for the services billed

Medicare patients

130

Average age 71

Services billed

297

57 women, 73 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 44%
Diabetes 32%
Ischemic heart disease 23%
Depression 20%
Cancer 19%
Atrial fibrillation 17%
Chronic kidney disease 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1,702 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record